VIVUS to Present at the Fourth Annual Robins Equity Research Round-Up

VIVUS, Inc., (NASDAQ: VVUS), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it will make a presentation at the Fourth Annual Robins Equity Research Round-Up hosted by Catalyst Research Management Group in Portland, Oregon.

The VIVUS, Inc. presentation will be made by CEO and Director John Amos on Tuesday, September 25th at 11:00 a.m. Pacific Time. The Robins Equity Research Round-Up is free to attend for brokers, money managers and private investors.

About VIVUS

VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit www.vivus.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2017 as filed on March 14, 2018, and as amended by the Form 10-K/A filed on April 26, 2018, and periodic reports filed with the Securities and Exchange Commission.

VIVUS, Inc.	Investor Relations: Lazar Partners
Mark Oki	David Carey
Chief Financial Officer	Managing Director
[e-mail]	[e-mail]
650-934-5200	212-867-1768